Lv3
352 积分 2023-08-16 加入
Prognostic Impact of Single Moderate Exacerbation in Patients With COPD
6天前
已完结
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
8天前
已完结
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
8天前
已完结
Clinical stability under FF/UMEC/VI triple inhaled therapy: A 12-month real life retrospective observational study
9天前
已完结
Biological Therapies in Chronic Obstructive Pulmonary Disease: New Directions in Personalised Respiratory Medicine
9天前
已完结
Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD
10天前
已完结
Clinical Outcomes in Patients With COPD With Disease Stability
11天前
已完结
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
12天前
已完结
Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV
14天前
已完结
Changes in small airway function following Dupilumab initiation for type 2 COPD – a prospective multicenter study
17天前
已完结